Cytokine Release Syndrome

It is associated with viral infections, sepsis, autoimmune diseases, and a variety of factors used in immunotherapy. The supplied grounding specifically links it to immune effector cell therapies, including CAR T-cell and other immune cell- or bispecific antibody-based approaches. No single cause is established in the grounding.

The core mechanism is hyperproduction of cytokines, producing an exaggerated inflammatory response. The grounding highlights cytokines including interleukin-6, interleukin-1beta, tumor necrosis factor-alpha, and interleukin-1 receptor antagonist protein, with signaling through cytokine receptors and downstream signal transduction pathways. This inflammatory cascade is associated with innate immunity activation, tissue injury, and in severe cases multi-organ failure.

The grounding supports risk from exposure to immunotherapy factors, especially immune effector cell therapies such as CAR T-cell and bispecific antibody-based approaches. Viral infection, sepsis, and autoimmune disease are also associated with the syndrome. In COVID-19, older age and comorbidities such as cardiovascular disease, diabetes, and obesity are described as increasing the chance of severe disease with cytokine storm.

The supplied grounding supports treatment at the modality level as cytokine-targeted and immune-response–modulating therapy. Tocilizumab is specifically co-studied, indicating use of IL-6–directed therapy, and the literature also discusses targeting cytokines more broadly to reduce the inflammatory cascade. In the immunotherapy setting, the focus is on management of cytokine release syndrome associated with immune effector cell therapies rather than a single universal regimen.